The UK and US have signed a landmark bilateral deal that will keep zero duties on British drug exports entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost spending on medicines through the NHS. This move guarantees that import taxes on these vital goods will be held at zero for a period of the next three years.
This deal follows earlier warnings to dramatically increase duties on patented drug products, with figures floated reaching one hundred percent.
"This arrangement with the Britain reinforces the global environment for cutting-edge drugs and introduces long-overdue fairness to U.S.–U.K. pharmaceutical trade," a statement said.
Commercial Significance
Pharmaceuticals are one of the UK's most significant goods shipped to the America, which is clearly the biggest buyer for leading companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period leading up to last September, the UK shipped medicines totaling over eleven billion pounds to the US. This value represented nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards work, increases investment and paves the way for the UK to emerge as a international leader for biotech and pharma," a minister remarked.
Detailed NHS Changes
The deal entails several notable pledges from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to double overall NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must return to the NHS to control costs will be limited at 15%. In the past, rebates were more than 20%.
Recent Tensions
The deal follows a ongoing row between the sector and the ministers over drug pricing and NHS adoption.
These tensions were heightened by assertions that US consumers were charged significantly more for the equivalent treatments than people in the Britain and the EU.
In recent months, several large drug company projects in the UK have been paused or abandoned, while substantial expansions have been pledged toward American operations.
A senior figure stated that the NHS must spend more on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the past decade.
